Total Payments
$109,693
2024 Payments
$6,408
Companies
12
Transactions
138
Medicare Patients
425
Medicare Billing
$45,384
Payment Breakdown by Category
Consulting$63,312 (57.7%)
Travel$23,364 (21.3%)
Other$17,130 (15.6%)
Food & Beverage$3,622 (3.3%)
Research$2,013 (1.8%)
Education$251.82 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $63,312 | 14 | 57.7% |
| Travel and Lodging | $23,364 | 58 | 21.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,130 | 7 | 11.1% |
| Honoraria | $5,000 | 2 | 4.6% |
| Food and Beverage | $3,622 | 43 | 3.3% |
| Unspecified | $2,013 | 10 | 1.8% |
| Education | $251.82 | 4 | 0.2% |
Payments by Type
General
$107,680
128 transactions
Research
$2,013
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic, Inc. | $27,825 | 43 | $0 (2024) |
| Eli Lilly and Company | $19,691 | 19 | $0 (2020) |
| Novo Nordisk Inc | $17,410 | 20 | $0 (2024) |
| Novo Nordisk AS | $12,140 | 6 | $0 (2017) |
| Medtronic MiniMed, Inc. | $10,256 | 15 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $8,111 | 7 | $0 (2018) |
| Trividia Health, Inc. | $4,973 | 3 | $0 (2017) |
| MannKind Corporation | $4,715 | 7 | $0 (2023) |
| Dexcom, Inc. | $1,694 | 3 | $0 (2018) |
| Corcept Therapeutics | $1,651 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,408 | 11 | Medtronic, Inc. ($6,376) |
| 2023 | $3,434 | 15 | Corcept Therapeutics ($1,651) |
| 2022 | $10,786 | 16 | Medtronic, Inc. ($10,786) |
| 2021 | $10,481 | 15 | Medtronic, Inc. ($10,481) |
| 2020 | $3,593 | 6 | Medtronic MiniMed, Inc. ($3,330) |
| 2019 | $22,763 | 25 | Eli Lilly and Company ($10,066) |
| 2018 | $28,478 | 30 | Eli Lilly and Company ($9,475) |
| 2017 | $23,750 | 20 | Novo Nordisk AS ($12,140) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 03/25/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: Durable Pump | ||||||
| 03/25/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Durable Pump | ||||||
| 03/11/2024 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,040.00 | General |
| 02/26/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Travel and Lodging | In-kind items and services | $124.46 | General |
| Category: Durable Pump | ||||||
| 02/22/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $48.00 | General |
| 02/15/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $41.30 | General |
| Category: Durable Pump | ||||||
| 02/13/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Travel and Lodging | In-kind items and services | $279.75 | General |
| Category: Durable Pump | ||||||
| 02/13/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $151.99 | General |
| Category: Durable Pump | ||||||
| 02/09/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Travel and Lodging | In-kind items and services | $616.29 | General |
| Category: Durable Pump | ||||||
| 02/09/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Travel and Lodging | In-kind items and services | $34.25 | General |
| Category: Durable Pump | ||||||
| 11/01/2023 | MannKind Corporation | AFREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/01/2023 | MannKind Corporation | AFREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/01/2023 | MannKind Corporation | AFREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/01/2023 | MannKind Corporation | AFREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: DIABETES MEDICINE | ||||||
| 06/28/2023 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $178.42 | General |
| Category: Durable Pump | ||||||
| 06/28/2023 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $4.08 | General |
| Category: Durable Pump | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $462.88 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $319.99 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $293.55 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $227.50 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $97.66 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $81.18 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $70.32 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $67.91 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CATALYST | Corcept Therapeutics | $1,584 | 8 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $429.62 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 94 | 148 | $41,041 | $9,968 |
| 2022 | 2 | 89 | 148 | $35,903 | $9,929 |
| 2021 | 3 | 103 | 178 | $39,402 | $12,798 |
| 2020 | 4 | 139 | 215 | $43,288 | $12,689 |
Total Patients
425
Total Services
689
Medicare Billing
$45,384
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 63 | 108 | $30,317 | $7,500 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 20 | $6,952 | $1,570 | 22.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 20 | $3,772 | $898.13 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 115 | $30,038 | $8,355 | 27.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 22 | 33 | $5,865 | $1,574 | 26.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 62 | 124 | $28,721 | $9,711 | 33.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 23 | 33 | $5,033 | $1,666 | 33.1% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2021 | 18 | 21 | $5,648 | $1,421 | 25.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 66 | 124 | $25,164 | $7,476 | 29.7% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 22 | 27 | $7,236 | $2,467 | 34.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 26 | 32 | $6,670 | $2,034 | 30.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 25 | 32 | $4,218 | $712.71 | 16.9% |
About Dr. Andrew Ahmann, MD
Dr. Andrew Ahmann, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891701405.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Ahmann, MD has received a total of $109,693 in payments from pharmaceutical and medical device companies, with $6,408 received in 2024. These payments were reported across 138 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($63,312).
As a Medicare-enrolled provider, Ahmann has provided services to 425 Medicare beneficiaries, totaling 689 services with total Medicare billing of $45,384. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Portland, OR
- Active Since 08/01/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1891701405
Products in Payments
- Victoza (Drug) $16,178
- Ozempic (Drug) $13,340
- NO PRODUCT DISCUSSED (Drug) $8,111
- AFREZZA (Drug) $4,715
- Korlym (Drug) $1,651
- DEXCOM CGM (Device) $1,500
- MINIMED 780G (Device) $1,470
- Minimed 670G System (Device) $1,287
- MINIMED 770G (Device) $1,199
- FreeStyle Libre Pro (Device) $1,036
- Minimed 770G System (Device) $997.73
- Dexcom G5 Mobile CGM System (Device) $193.70
- FreeStyle Lite system (Device) $139.80
- Wegovy (Drug) $32.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Portland
Mr. Michael Mcclung, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.6M
Endocrinology, Diabetes & Metabolism $1.6M
James Neifing, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $475,019
Endocrinology, Diabetes & Metabolism $475,019
Maria Fleseriu, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $418,716
Endocrinology, Diabetes & Metabolism $418,716
Rodica Busui, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $211,479
Endocrinology, Diabetes & Metabolism $211,479
Jonathan Purnell, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $209,631
Endocrinology, Diabetes & Metabolism $209,631
Nancy Curosh, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $194,307
Endocrinology, Diabetes & Metabolism $194,307